ArticleJournal of spine surgery (Hong Kong)2026
L5-S1 basivertebral nerve ablation for chronic vertebrogenic low back pain following lumbar fusion: a case report.
Article in Journal of spine surgery (Hong Kong), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Basivertebral nerve ablation (BVNA) is an established treatment for vertebrogenic low back pain associated with Modic endplate changes, but trials and current on-label use have excluded patients with prior lumbar fusion. The clinical efficacy of BVNA has been established in the SMART (Surgical Multi-Center Assessment of RF Therapy) and INTRACEPT trials. Patients with prior lumbar fusion with symptomatic vertebrogenic low back pain were excluded from these major trials, but remain a clinically significant subgroup of patients who may benefit from BVNA. Case Description: A 55-year-old man presented with severe chronic axial low back pain persisting for more than 5 years after stand-alone L5-S1 interbody fusion performed in 1995. Pain was predominantly midline and mechanical, worsened by sitting, bending, lifting, and driving, and improved with standing or walking. He had failed extensive conservative and interventional therapies including nonsteroidal anti-inflammatory drugs, acetaminophen, epidural steroid injections, facet injections, medial branch blocks, sacroiliac joint injections, radiofrequency ablations, prolotherapy, acupuncture, and chiropractic care. Preoperative visual analog scale (VAS) score was 7/10 and Oswestry Disability Index (ODI) was 48%. Computed tomography showed a stable fusion construct without evidence of pseudoarthrosis or hardware complication. Magnetic resonance imaging demonstrated Modic type 2 endplate changes at L5-S1 adjacent to the fusion cages, supporting a vertebrogenic pain generator. The patient underwent fluoroscopically guided BVNA at L5 and S1 without complication. At 12 months, VAS was 3/10 and ODI 16%, exceeding the minimum clinically important difference (MCID) for spine surgery. The patient reported a 75% subjective improvement and return to unrestricted occupational activity. Conclusions: This case suggests that off-label BVNA may provide meaningful and durable relief in carefully selected post-fusion patients with persistent vertebrogenic pain and persistent Modic changes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.